APA (7th ed.) Citation

DL, Y., L, Y., FJ, Z., J, L., HB, Y., JL, N., . . . JH, Z. (2025). Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages. Hepatology (Baltimore, Md.), 82(2), E40. https://doi.org/10.1097/HEP.0000000000001401

Chicago Style (17th ed.) Citation

DL, Yang, et al. "Erratum: Multicenter, Retrospective GUIDANCE001 Study Comparing Transarterial Chemoembolization with or Without Tyrosine Kinase and Immune Checkpoint Inhibitors as Conversion Therapy to Treat Unresectable Hepatocellular Carcinoma: Survival Benefit in Intermediate or Advanced, but Not Early, Stages." Hepatology (Baltimore, Md.) 82, no. 2 (2025): E40. https://doi.org/10.1097/HEP.0000000000001401.

MLA (9th ed.) Citation

DL, Yang, et al. "Erratum: Multicenter, Retrospective GUIDANCE001 Study Comparing Transarterial Chemoembolization with or Without Tyrosine Kinase and Immune Checkpoint Inhibitors as Conversion Therapy to Treat Unresectable Hepatocellular Carcinoma: Survival Benefit in Intermediate or Advanced, but Not Early, Stages." Hepatology (Baltimore, Md.), vol. 82, no. 2, 2025, p. E40, https://doi.org/10.1097/HEP.0000000000001401.